Étiquette : CBD

Analyse et position de NORML France sur les produits dérivés chanvre CBD, NORML France, par Olivier Bertrand | Juin 13, 2018 |

Analyse et position de NORML France sur les produits dérivés chanvre CBD NORML France, par Olivier Bertrand | Juin 13, 2018 | https://www.norml.fr/la-position-de-norml-france-sur-le-chanvre-cbd-et-les-nouvelles-boutiques-chanvre/ Alors que les fleurs de chanvre industrielles étaient méprisées du grand public jusqu’à récemment, les voici désormais sous les phares des projecteurs médiatiques avec la vague de nouvelles boutiques CBD qui déferle sur la France actuellement. Par quel miracle transforme t-on un déchet de l’agriculture du chanvre en un produit hautement valorisable ? Pourquoi un tel engouement pour un produit qui n’intéressait naguère absolument personne? Le cannabidiol, la nouvelle substance active en vogue du cannabis. La construction moléculaire du CBD, très proche [...]

Lire la suite

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique, Dr Christian SUEUR, USSAP – GRECC, avril 2021

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, CSAPA / USSAP Carcassonne, GRECC. Dr Christian SUEUR, avril 2021. 93 pages   Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1] En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout [...]

Lire la suite

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis, Sara Arias et al., 2021

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis Sara Arias, Marta Leon, Diego Jaimes and Rosa-Helena Bustos Pharmaceuticals, 2021, 14, 78, 1-13. Doi :10.3390/ph14020078   Abstract : Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment [...]

Lire la suite

Cannabis-Based Oral Formulations for Medical Purposes : Preparation, Quality and Stability, Francesca Baratta et al., 2021

Cannabis-Based Oral Formulations for Medical Purposes : Preparation, Quality and Stability Francesca Baratta, Marco Simiele, Irene Pignata, Lorenzo Ravetto Enri, Antonio D’Avolio, Riccardo Torta, Anna De Luca, Massimo Collino and Paola Brusa Pharmaceuticals, 2021, 14, 171, 1-13. Doi : 10.3390/ph14020171   Abstract : Current legislation in Italy provides that medical Cannabis may be administered orally or by inhalation. One of the fundamental criteria for the administration of oral formulations is that they deliver a known consistent quantity of the active ingredients to ensure uniform therapies leading to the optimisation of the risks/benefits. In 2018, our group developed an improved Cannabis oil extraction technique. The objective of [...]

Lire la suite

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment, Anna Stasiłowicz et al., 2021

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment Anna Stasiłowicz, Anna Tomala, Irma Podolak and Judyta Cielecka-Piontek International Journal of Molecular Sciences, 2021, 22, 778. Doi : 10.3390/ijms22020778 Abstract : Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results [...]

Lire la suite

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain, Marta Vázquez et al., 2020,

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain Marta Vázquez, Natalia Guevara, Cecilia Maldonado, Paulo Cáceres Guido, and Paula Schaiquevich Hindawi, BioMed Research International, 2020, Article ID 3902740, 9 pages Doi : 10.1155/2020/3902740 Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between [...]

Lire la suite

An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom, Jonathan Paul Liebling et al., 2020

An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom Jonathan Paul Liebling, Nicholas James Clarkson, Blair William Gibbs, Andrew Stephen Yates, and Saoirse Elizabeth O’Sullivan Cannabis and Cannabinoid Research, 2020, 1-7. DOI: 10.1089/can.2019.0078   Abstract Introduction : Over-the-counter cannabidiol (CBD) products have seen unprecedented recent growth in the United Kingdom. However, analysis of these predominantly unregulated products from other countries tells us that they are often mislabeled or contain unlabeled and potentially dangerous chemicals. Thus, the aim of the present study was to analyze CBD oils available in the United Kingdom. Materials and Methods: Phytocannabinoids, residual solvent, and heavy metals were measured blinded in 29 [...]

Lire la suite

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe and Mohini Ranganathan Neuropsychopharmacology Reviews, 2018, 43, 142–154. doi : 10.1038/npp.2017.209; The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are 4550 chemical compounds and 4100 phytocannabinoids [...]

Lire la suite

Les interactions CBD / médicaments, Swiss Medical Cannabis, 2020

Les interactions CBD / médicaments Posté le 6 avril 2020 par Swiss Medical Cannabis   Depuis l’augmentation de sa demande, le cannabidiol (CBD) attire significativement l’attention sur son potentiel à soulager les symptômes de l’insomnie, de l’anxiété, de la douleur chronique et d’une foule d’autres problèmes de santé. Les recherches menées à ce jour démontrent progressivement que le CBD est d’une grande sécurité d’emploi même à forte dose et peu d’effets secondaires, somme toute mineurs. Toutefois, il existe une mise en garde : le CBD peut interagir avec certains médicaments. L’interrogation porte ainsi sur la façon dont le corps métabolise certaines substances. Avant de [...]

Lire la suite

The Impact of Cannabidiol on Psychiatric and Medical Conditions, Thersilla Oberbarnscheidt & Norman S. Miller, 2019

The Impact of Cannabidiol on Psychiatric and Medical Conditions Thersilla Oberbarnscheidt, Norman S. Miller Journal of Clinical and Medical Research, 2020, 12, (7), 393-403. Doi : 10.14740/jocmr4159   Abstract Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical [...]

Lire la suite